Yorlabs

Executive Summary

Yorlabs is a San Diego-based medical device company founded in 2019, focused on revolutionizing intracardiac image-guided therapy for interventional cardiology and electrophysiology. The company addresses the limitations of current ultrasound systems, which are sub-optimal, expensive, and cause workflow inefficiencies, cognitive overload, and procedural complexity. Yorlabs aims to set a new diagnostic standard by developing a simplified, purpose-built imaging platform designed to streamline procedures and improve outcomes. By targeting the underserved needs of cardiologists and electrophysiologists, the company seeks to enhance procedural efficiency, reduce cognitive burden, and lower costs in catheter-based interventions. Given the growing prevalence of cardiac arrhythmias and structural heart disease, the market opportunity for advanced intracardiac imaging is significant. Yorlabs' solution has the potential to become a standard tool in hybrid operating rooms and electrophysiology labs. The company is likely in the product development and regulatory clearance stage, with a focus on obtaining FDA 510(k) clearance and building clinical evidence. Its success hinges on demonstrating superior image quality, ease of use, and cost-effectiveness compared to existing alternatives. With a clear clinical need and a focused approach, Yorlabs is positioned to disrupt the intracardiac imaging market.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Core Imaging System60% success
• Q2 2026First-In-Human Clinical Study Initiation50% success
• Q3 2026Series A Funding Round Completion70% success